In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
AZD2563 is a new oxazolidinone that has targeted activity against Gram-positive bacteria. The in vitro activity of AZD2563 and nine comparators against 1543 European enterococcal, staphylococcal and streptococcal isolates was determined. The compound is a potent oxazolidinone, with no isolate tested displaying an MIC > 4 mg/L and 94.4% having an MIC < or =2 mg/L. Compared with linezolid, the distribution of MICs for all species of bacteria tested, with the exception of Enterococcus faecium, was shifted by one or two dilution steps to lower values for AZD2563. Thus, this oxazolidinone is a promising new antibiotic for the treatment of infections with Gram-positive cocci.
Fluit
A C
AC
Eijkman-Winkler Center, UMCU, Room G04. 614, PO Box 85500, 3508 GA Utrecht, The Netherlands. A.C.Fluit@lab.azu.nl
Schmitz
F-J
FJ
Verhoef
J
J
Milatovic
D
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D013293:Enterococcus faecalis / Q000187:drug effects / Q000302:isolation & purification; D016984:Enterococcus faecium / Q000187:drug effects / Q000302:isolation & purification; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D023303:Oxazolidinones / Q000494:pharmacology*; D013291:Streptococcus / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; C453362:posizolid